Valuation: Gabather AB

Market Cap 13.43M 1.36M 1.21M 1.12M 1.02M 1.92M 129M 1.95M 5.27M 67.17M 5.09M 4.98M 214M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 10.29M 1.04M 923K 856K 779K 1.47M 98.59M 1.49M 4.03M 51.45M 3.9M 3.82M 164M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
91.04%
Yield 2024 *
-
Yield 2025 -
1 day-6.78%
1 week-8.33%
Current month-21.43%
1 month-17.29%
3 months-33.33%
6 months-37.85%
Current year-19.71%
1 week 0.02
Extreme 0.0204
0.03
1 month 0.02
Extreme 0.0204
0.03
Current year 0.02
Extreme 0.0204
0.1
1 year 0.02
Extreme 0.0204
0.1
3 years 0.02
Extreme 0.0204
4.2
5 years 0.02
Extreme 0.0204
6.55
10 years 0.02
Extreme 0.0204
53.2
Manager TitleAgeSince
Chief Executive Officer - 30/09/2018
Chief Operating Officer - 31/12/2017
Chief Tech/Sci/R&D Officer - 31/12/2017
Director TitleAgeSince
Director/Board Member - 31/08/2014
Director/Board Member 60 02/11/2014
Director/Board Member 63 29/06/2023
Change 5-day change 1-year change 3-year change Capi.($)
-6.78%-8.33%-24.14%-99.02% 1.36M
-6.60%-8.56%+42.79%+64.16% 65B
-4.09%-0.11%+2.31%+54.81% 51.19B
+0.03%+5.56%+10.18%+41.75% 51.2B
-1.53%+2.70%+29.72%+34.13% 43.93B
-1.34%+4.12%+16.05%+112.18% 41.96B
-5.97%-6.22%+258.21%+421.57% 38.14B
+6.53%+8.02%+15.74%+53.94% 33.24B
-0.90%-10.49%+31.48%-1.63% 25.2B
-2.76%-9.54%-16.53%-9.55% 22.03B
Average -2.34%-2.70%+36.58%+67.23% 37.19B
Weighted average by Cap. -2.30%-1.21%+43.56%+88.58%

Financials

2024 2025
Net sales - -
Net income -7.75M -783K -696K -645K -587K -1.11M -74.3M -1.13M -3.04M -38.77M -2.94M -2.88M -124M -4.65M -470K -418K -387K -352K -664K -44.58M -675K -1.82M -23.26M -1.76M -1.73M -74.16M
Net Debt -878K -88.66K -78.81K -73.04K -66.46K -125K -8.41M -127K -344K -4.39M -333K -326K -14M -3.14M -317K -282K -261K -238K -449K -30.12M -456K -1.23M -15.72M -1.19M -1.17M -50.11M
Projected Income Statement - Annual - Gabather AB
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
16/10/26 SEK 0.0220 -6.78% 2,922,652
15/10/26 SEK 0.0236 -1.67% 2,593,778
14/10/26 SEK 0.0240 -7.69% 4,605,189
13/10/26 SEK 0.0260 +4.00% 1,443,470
12/10/26 SEK 0.0250 +4.17% 1,331,031
  1. Stock Market
  2. Stocks
  3. GABA Stock